AGT and diabetic kidney disease: In addition, a post-hoc analysis of the reduction in endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan trial and the Irbesartan Diabetic Nephropathy Trial both reported associations between a high bilirubin level and decreased composite renal endpoint of a two-fold increase in serum creatinine or ESRD among patients with diabetic nephropathy.